Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Other Non-Current Assets (2016 - 2025)

Historic Other Non-Current Assets for Zevra Therapeutics (ZVRA) over the last 11 years, with Q3 2025 value amounting to $153000.0.

  • Zevra Therapeutics' Other Non-Current Assets fell 7011.72% to $153000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $153000.0, marking a year-over-year decrease of 7011.72%. This contributed to the annual value of $384000.0 for FY2024, which is 30851.06% up from last year.
  • According to the latest figures from Q3 2025, Zevra Therapeutics' Other Non-Current Assets is $153000.0, which was down 7011.72% from $220000.0 recorded in Q2 2025.
  • Zevra Therapeutics' Other Non-Current Assets' 5-year high stood at $1.8 million during Q1 2024, with a 5-year trough of $53000.0 in Q4 2022.
  • In the last 5 years, Zevra Therapeutics' Other Non-Current Assets had a median value of $437000.0 in 2021 and averaged $404789.5.
  • Its Other Non-Current Assets has fluctuated over the past 5 years, first tumbled by 8795.45% in 2023, then soared by 326981.13% in 2024.
  • Zevra Therapeutics' Other Non-Current Assets (Quarter) stood at $438000.0 in 2021, then crashed by 87.9% to $53000.0 in 2022, then skyrocketed by 77.36% to $94000.0 in 2023, then soared by 308.51% to $384000.0 in 2024, then plummeted by 60.16% to $153000.0 in 2025.
  • Its last three reported values are $153000.0 in Q3 2025, $220000.0 for Q2 2025, and $293000.0 during Q1 2025.